Proteolix, Inc. discovers and develops pharmaceutical products that target certain cancers and immunological conditions by inhibiting the proteasome and thereby disrupting protein turnover in cells. Our lead product candidate, carfilzomib (PR-171), is currently in multiple clinical trials to evaluate its safety and efficacy for the treatment of multiple – more... myeloma, lymphoma and certain solid tumor malignancies. In addition, Proteolix is developing next generation proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor, to expand the therapeutic potential of this new target class. Proteolix is privately-held and headquartered in South San Francisco. – less – More from ZoomInfo »
Proteolix inc Employer Reviews
